Researchers in one previous study on patients with long-standing RA treated with MTX or anti-tumor necrosis factor drugs tested the use of Fc galactosylation status as a biomarker for predicting MTX response [16]. The gene discussed is TNF; the disease is rheumatoid arthritis.